TP53 and B-cell chronic lymphocytic leukemia: In prostate cancer, TP53 mutations have been demonstrated to be closely associated with high-grade differentiation, disease progression, and therapeutic resistance, while in chronic lymphocytic leukemia (CLL), TP53 aberrations are well-established molecular markers of poor prognosis (17, 18).